Novigenix
17.1.2024 08:02:15 CET | ACCESS Newswire | Press release
GENEVA, SWITZERLAND / ACCESSWIRE / January 17, 2024 / With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Personalized Cancer Treatment: Breaking Barriers
Every cancer is as unique as the person it affects. Tumors are in continuous dynamic interplay with the patient's immune defenses and are adept at subverting and escaping immune control. Novigenix is on a mission to improve the cancer treatment landscape, leveraging advanced AI and RNA analysis from a routine blood draw to provide more precise insights into patient immune responses to cancer treatments, compared to conventional DNA liquid biopsies that evaluate tumor evolution through circulating tumor DNA (ctDNA). Insights into the precise dynamic of patient immune response thus pave the way for superior therapeutic discoveries in the field.
Empowering Biopharma: Unveiling LITOSeek™ at Precision Medicine World Conference
On January 24th at the Precision Medicine World Conference in Silicon Valley, Novigenix will debut LITOSeek™, a groundbreaking solution designed to expedite drug development for biopharma companies.
AI and RNA Analysis: Pioneering Healthcare Transformation
With a decade-long track record, Novigenix successfully launched Colox® blood test in Switzerland, powered by AI and RNA analysis to detect early-stage colon cancer, marking a significant departure from invasive colonoscopy procedures. By aggregating data from diverse colon cancer patients, Novigenix identified immune system biomarkers crucial for early-stage detection, enhancing treatment outcomes.
Dr. Brian Hashemi, Novigenix's CEO and Chairman, emphasized, "Our experience with Colox® underscores the potential of AI RNA analysis. Ongoing studies across various cancer types have fuelled our Knowledge Base to uncover comprehensive sets of biomarkers via liquid biopsy and AI RNA analysis. Our validated immunotherapy response biomarkers provide early prediction of patient response and we invite biopharma companies to leverage our platform for more efficient and effective drug development."
Professor Pedro Romero, M.D. Chief Medical & Scientific Officer of Novigenix, and Founding Chief Editor of the Journal of Immunotherapy of Cancer, highlights the importance of patient immune response in the development of novel therapies: "AI RNA analysis is poised to revolutionize healthcare, accelerating conventional experimental drug development with data-driven precision immune response prediction. By swiftly analyzing systemic immune responses, AI compresses analysis times, expediting traditional drug development and powering discovery of novel therapy targets."
A Team Dedicated to the Future of Cancer Care
With over 20 Ph.D.-level scientists focused on the development of the LITOSeek™ platform and advancing next-generation liquid biopsy solutions, Novigenix is pioneering precision immunology to help transform cancer treatment paradigms for better patient outcomes.
#Ends#
[1] https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/
Contact Information
Edwin Shankar
edwin.shankar@leidar.com
SOURCE: Novigenix
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
POLARIS Laboratories Joins the Dow Coolant Care Network as Testing Provider for DOWFROST Heat Transfer Fluids28.5.2026 15:00:00 CEST | Press release
INDIANAPOLIS, IN / ACCESS Newswire / May 28, 2026 / POLARIS Laboratories® today announced Dow has selected POLARIS Laboratories® as a testing provider for DOWFROST™ LC and HD Heat Transfer Fluids used in advanced cooling systems. This collaboration reinforces Dow's commitment to helping customers move beyond reactive maintenance practices toward proactive, data-driven fluid management. DOWFROST™ Heat Transfer Fluids are engineered to support next-generation data center cooling, including direct-to-chip liquid cooling architectures. Formulated with high-purity propylene glycol and advanced inhibitor technology, these fluids enable efficient heat removal, corrosion protection, and long-term operational stability in high-performance computing environments. To meet thermal demands from Artificial Intelligence (AI) and high-density computing, monitoring liquid cooling fluid is critical to protect uptime, maintain performance and reduce operational risk. The Dow Coolant Care Network integrat
Caldwell Strengthens Financial Services and Fintech Capabilities with Addition of Alex Langridge in London28.5.2026 10:30:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / May 28, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Alex Langridge as a Partner in the firm's Financial Services Practice. Based in London, Langridge advises clients across financial services and fintech on senior executive and board appointments, succession planning, organizational design, and transformational leadership hiring. Based in London, Alex Langridge joins Caldwell's Financial Services Practice, bringing deep expertise across banking, fintech, insurance, and transformational leadership advisory. Langridge brings more than 20 years of executive search and leadership advisory experience, partnering with banks, insurers, fintechs, and private equity- and venture-backed businesses across the UK and EMEA. He is particularly known for placing P&L, operations, commercial, product, technology, and digital leaders into high-impact transformational roles, as well as for helping cli
Applications are Open for the 2026 Semmelweis-Richter Journalism Award Until June 9th28.5.2026 09:00:00 CEST | Press release
BUDAPEST, HUNGARY / ACCESS Newswire / May 28, 2026 / After the strong success of its first edition, the Semmelweis-Richter Journalism Award returns in 2026. Journalists from eligible European countries are invited to submit entries in two categories: Women's Health and Pharmaceutical Strategies and Innovation, with a special focus on cardiovascular therapies. The application deadline is June 9, 2026, 23:59 CET. The international award was first launched in 2025 by Semmelweis University, Hungary's leading medical and health sciences university, with the support of Gedeon Richter, a Hungary-based, innovation-focused multinational pharmaceutical company. The award aims to recognise high-quality health journalism and its role in informing the public and shaping health-related debate across Europe. The first edition attracted wide international interest, with nearly 70 submissions from more than 20 European countries, including the United Kingdom, Germany, and Russia. Entries were published
Miami Fashion Week Successfully Launches Inaugural Virtual Fashion Awards Gala at Queen Miami Beach27.5.2026 18:00:00 CEST | Press release
A groundbreaking evening celebrating the future of fashion through technology, creativity, and innovation brought together global designers, AI-powered runway premieres, and industry recognition. MIAMI, FL / ACCESS Newswire / May 27, 2026 / Miami Fashion Week (MIAFW) successfully hosted its inaugural Virtual Fashion Awards on May 21, 2026, at Queen Miami Beach, hosted by Emmy Award-Winning Journalist, Lisa Petrillo. The exclusive in-person event welcomed global fashion leaders, designers, and innovators for an evening dedicated to creativity, technology, and the evolving future of fashion. Blending physical and digital experiences, the gala featured both produced and in-development collections, highlighting the fusion of emerging technologies with traditional craftsmanship. A live model showcase complemented the AI-powered virtual runway presentations, creating a fully immersive experience for attendees. Images (Courtesy of Miami Fashion Week): here Official Gala Recap and Virtual Pres
OMP Launches Unison Express to Fast-Track Supply Chain Planning from Ambition to Early Value27.5.2026 15:00:00 CEST | Press release
Ready-to-deploy solution delivers value quickly through proven industry best practices ANTWERPEN, BE / ACCESS Newswire / May 27, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, today announced the launch of Unison Express - an industry-specific, ready-to-deploy planning offering for mid-market companies looking to move beyond the tools and processes they have outgrown. Unison Express enables teams to realize value quickly while establishing a strong planning foundation that scales with their business over time. From spreadsheets to structured planning Organizations across industries face mounting pressure to modernize supply chain planning. Yet implementation projects can feel long, costly, and difficult to justify, especially when teams still rely on tools and processes they have outgrown, such as spreadsheets, legacy systems, and manual coordination. The result is higher operational risk and slower, less coordinated decision-making. Unison Express bridge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom